{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '147', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.7', 'Appendix 7: Country-specific Requirements', '10.7.1', 'Japan-specific Requirements', 'For the assistance to early diagnosis of pneumonitis/interstitia lung disease (ILD) in study', 'participants, the following items, such as pulse oximetry monitoring (peripheral capillary', 'oxygen saturation [SpO2]), C-reactive protein (CRP), Krebs von den Lungen-6 (KL-6), and', 'surfactant protein-D (SP-D), will be measured in this study. These items should be measured', 'as follows:', 'SpO2 at the timing of vital sign assessment', 'CRP, KL-6, and SP-D at screening*, predose on Day 1 of every cycle, end of', 'treatment, and the Safety Follow-up Visit (30 days after last dose)', '*Should be measured at the timing of clinical laboratory tests (such as', 'hematology/chemistry)', 'If pneumonitis/ILD occurs regardless of causality with study intervention, an independent', 'ILD evaluation committee will conduct adjudication of cases of the pneumonitis/ILD. For', 'this purpose, relevant data, such as chest imaging (from the baseline to the recovery of', 'pneumonitis/ILD) will be submitted to MSD K.K.', '10.7.2', 'France-specific Requirements', 'Treatment with pembrolizumab should be permanently discontinued in cases of confirmed', 'Stevens-Johnson syndrome or toxic epidermal necrolysis.', '10.7.3', 'Canada-specific Requirements', 'See Section 6.6.1 Immune-related Events and Dose Modification (Withhold, Treat,', 'Discontinue)', 'Treatment with pembrolizumab should be permanently discontinued in cases of confirmed', 'Stevens-Johnson syndrome or toxic epidermal necrolysis.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '148', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.8', 'Appendix 8: Abbreviations', 'Abbreviation', 'Expanded Term', '1L', 'first-line', 'ADA', 'antidrug antibody', 'ADL', 'activities of daily living', 'AE', 'adverse event', 'AJCC', 'American Joint Committee on Cancer', 'ALK', 'anaplastic lymphoma kinase', 'APaT', 'All Participants as Treated', 'BICR', 'blinded independent central review', 'CI', 'confidence interval', 'CL', 'clearance', 'COPD', 'chronic obstructive pulmonary disease', 'CR', 'complete response', 'CRF', 'case report form', 'CRP', 'C-reactive protein', 'CSR', 'clinical study report', 'CT', 'computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CTFG', 'Clinical Trial Facilitation Group', 'CVA', 'cerebrovascular accident', 'DILI', 'drug-induced liver injury', 'DMC', 'data monitoring committee', 'DNA', 'deoxyribonucleic acid', 'DOR', 'duration of response', 'ECG', 'electrocardiogram', 'ECI', 'event of clinical interest', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'electronic case report form', 'EDC', 'electronic data collection', 'EGFR', 'epidermal growth factor receptor', 'EMA', 'European Medicines Agency', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '149', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Abbreviation', 'Expanded Term', 'EOC', 'Executive Oversight Committee', 'EORTC', 'European Organization for Research and Treatment of Cancer', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D-5L', 'EuroQoL-5D-5L', 'FAS', 'Full Analysis Set', 'FDA', 'Food and Drug Administration', 'FDAAA', 'Food and Drug Administration Amendments Act', 'FGF', 'fibroblast growth factor', 'FGFR', 'fibroblast growth factor receptor', 'FSH', 'follicle-stimulating hormone', 'GCP', 'Good Clinical Practice', 'HBsAg', 'hepatitis B surface antigen', 'HBV', 'hepatitis B virus', 'HCV', 'hepatitis C virus', 'HIV', 'human immunodeficiency virus', 'HR', 'hazard ratio', 'HRQoL', 'health-related quality of life', 'HRT', 'hormone replacement therapy', 'IA', 'interim analysis', 'IB', \"Investigator's Brochure\", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation of Technical Requirements for', 'Pharmaceuticals for Human Use', 'iCPD', 'confirmed PD', 'iCR', 'confirmed CR', 'IEC', 'Independent Ethics Committee', 'irAE', 'immune-related adverse event', 'iPR', 'confirmed PR', 'IRB', 'Institutional Review Board', 'iRECIST', 'adjusted RECIST 1.1 for Immune-based Therapeutics', 'iSD', 'confirmed SD', 'ITT', 'Intention to Treat', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}